Biomark Diagnostics Stock Market Value
| BMKDF Stock | USD 0.24 0.02 7.69% |
| Symbol | BioMark |
BioMark Diagnostics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BioMark Diagnostics' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BioMark Diagnostics.
| 04/21/2025 |
| 07/20/2025 |
If you would invest 0.00 in BioMark Diagnostics on April 21, 2025 and sell it all today you would earn a total of 0.00 from holding BioMark Diagnostics or generate 0.0% return on investment in BioMark Diagnostics over 90 days. BioMark Diagnostics is related to or competes with Spectral Med, BioAffinity Technologies,, and VentriPoint Diagnostics. BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and asse... More
BioMark Diagnostics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BioMark Diagnostics' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BioMark Diagnostics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.75 | |||
| Information Ratio | 0.0807 | |||
| Maximum Drawdown | 37.69 | |||
| Value At Risk | (7.69) | |||
| Potential Upside | 8.33 |
BioMark Diagnostics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioMark Diagnostics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BioMark Diagnostics' standard deviation. In reality, there are many statistical measures that can use BioMark Diagnostics historical prices to predict the future BioMark Diagnostics' volatility.| Risk Adjusted Performance | 0.1072 | |||
| Jensen Alpha | 0.5962 | |||
| Total Risk Alpha | (0.20) | |||
| Sortino Ratio | 0.0584 | |||
| Treynor Ratio | (6.02) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of BioMark Diagnostics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
BioMark Diagnostics Backtested Returns
BioMark Diagnostics appears to be out of control, given 3 months investment horizon. BioMark Diagnostics secures Sharpe Ratio (or Efficiency) of 0.11, which signifies that the company had a 0.11 % return per unit of risk over the last 3 months. By analyzing BioMark Diagnostics' technical indicators, you can evaluate if the expected return of 0.59% is justified by implied risk. Please makes use of BioMark Diagnostics' Mean Deviation of 2.94, risk adjusted performance of 0.1072, and Downside Deviation of 7.75 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, BioMark Diagnostics holds a performance score of 8. The firm shows a Beta (market volatility) of -0.0969, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning BioMark Diagnostics are expected to decrease at a much lower rate. During the bear market, BioMark Diagnostics is likely to outperform the market. Please check BioMark Diagnostics' downside variance, rate of daily change, and the relationship between the maximum drawdown and skewness , to make a quick decision on whether BioMark Diagnostics' price patterns will revert.
Auto-correlation | 0.34 |
Below average predictability
BioMark Diagnostics has below average predictability. Overlapping area represents the amount of predictability between BioMark Diagnostics time series from 21st of April 2025 to 5th of June 2025 and 5th of June 2025 to 20th of July 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BioMark Diagnostics price movement. The serial correlation of 0.34 indicates that nearly 34.0% of current BioMark Diagnostics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.34 | |
| Spearman Rank Test | 0.72 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
BioMark Diagnostics lagged returns against current returns
Autocorrelation, which is BioMark Diagnostics otc stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting BioMark Diagnostics' otc stock expected returns. We can calculate the autocorrelation of BioMark Diagnostics returns to help us make a trade decision. For example, suppose you find that BioMark Diagnostics has exhibited high autocorrelation historically, and you observe that the otc stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
BioMark Diagnostics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If BioMark Diagnostics otc stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if BioMark Diagnostics otc stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in BioMark Diagnostics otc stock over time.
Current vs Lagged Prices |
| Timeline |
BioMark Diagnostics Lagged Returns
When evaluating BioMark Diagnostics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of BioMark Diagnostics otc stock have on its future price. BioMark Diagnostics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, BioMark Diagnostics autocorrelation shows the relationship between BioMark Diagnostics otc stock current value and its past values and can show if there is a momentum factor associated with investing in BioMark Diagnostics.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
Other Information on Investing in BioMark OTC Stock
BioMark Diagnostics financial ratios help investors to determine whether BioMark OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioMark with respect to the benefits of owning BioMark Diagnostics security.